PMC:5848803 / 1957-3187 JSONTXT

{"project":"0_colil","denotations":[{"id":"28505298-24623172-5294","span":{"begin":73,"end":74},"obj":"24623172"},{"id":"28505298-24623172-5295","span":{"begin":171,"end":172},"obj":"24623172"},{"id":"28505298-16242445-5296","span":{"begin":312,"end":313},"obj":"16242445"},{"id":"28505298-23321128-5297","span":{"begin":315,"end":316},"obj":"23321128"},{"id":"28505298-16242445-5298","span":{"begin":447,"end":448},"obj":"16242445"},{"id":"28505298-23321128-5299","span":{"begin":450,"end":451},"obj":"23321128"},{"id":"28505298-26704310-5300","span":{"begin":587,"end":588},"obj":"26704310"},{"id":"28505298-15245460-5301","span":{"begin":732,"end":733},"obj":"15245460"},{"id":"28505298-24623172-5302","span":{"begin":879,"end":880},"obj":"24623172"},{"id":"28505298-15245460-5303","span":{"begin":882,"end":883},"obj":"15245460"},{"id":"28505298-18329464-5304","span":{"begin":885,"end":886},"obj":"18329464"}],"text":"Redo cardiac surgery represents 5–8% of the current surgical practice [1–4]. In particular, reoperative coronary artery bypass grafting (redo-CABG) remains challenging [1–4] with prolonged operation time, bleeding, poor access to coronary targets and risk of coronary microembolization leading to complications [2, 3]. Redo-CABG has declined over the last decade to 2.5–4% of all coronary procedures, probably due to improved platelet inhibition [2, 3], use of more arterial conduits or to the use of percutaneous coronary intervention stenting to treat occluded grafts or new stenosis [5]. Poor risk profile in these patients may trigger complications associated with prolonged cardiopulmonary bypass and cardioplegic arrest time [6]. Studies from North America, Japan and India have highlighted the use of off-pump CABG as an alternative to redo coronary surgery (redo-OPCAB) [1, 6, 7]. However, most of these studies are based on small patient cohorts, and none of these studies has evaluated the impact of redo-OPCAB on long-term survival. In this study, we assess the safety and efficacy of redo-OPCAB versus redo-CABG using a combined end-point of serious postoperative complications as well as 1-, 5-, and 10-year survival."}

{"project":"TEST0","denotations":[{"id":"28505298-73-78-5294","span":{"begin":73,"end":74},"obj":"[\"24623172\"]"},{"id":"28505298-94-99-5295","span":{"begin":171,"end":172},"obj":"[\"24623172\"]"},{"id":"28505298-235-240-5296","span":{"begin":312,"end":313},"obj":"[\"16242445\"]"},{"id":"28505298-238-243-5297","span":{"begin":315,"end":316},"obj":"[\"23321128\"]"},{"id":"28505298-128-133-5298","span":{"begin":447,"end":448},"obj":"[\"16242445\"]"},{"id":"28505298-131-136-5299","span":{"begin":450,"end":451},"obj":"[\"23321128\"]"},{"id":"28505298-236-241-5300","span":{"begin":587,"end":588},"obj":"[\"26704310\"]"},{"id":"28505298-141-146-5301","span":{"begin":732,"end":733},"obj":"[\"15245460\"]"},{"id":"28505298-143-148-5302","span":{"begin":879,"end":880},"obj":"[\"24623172\"]"},{"id":"28505298-146-151-5303","span":{"begin":882,"end":883},"obj":"[\"15245460\"]"},{"id":"28505298-149-154-5304","span":{"begin":885,"end":886},"obj":"[\"18329464\"]"}],"text":"Redo cardiac surgery represents 5–8% of the current surgical practice [1–4]. In particular, reoperative coronary artery bypass grafting (redo-CABG) remains challenging [1–4] with prolonged operation time, bleeding, poor access to coronary targets and risk of coronary microembolization leading to complications [2, 3]. Redo-CABG has declined over the last decade to 2.5–4% of all coronary procedures, probably due to improved platelet inhibition [2, 3], use of more arterial conduits or to the use of percutaneous coronary intervention stenting to treat occluded grafts or new stenosis [5]. Poor risk profile in these patients may trigger complications associated with prolonged cardiopulmonary bypass and cardioplegic arrest time [6]. Studies from North America, Japan and India have highlighted the use of off-pump CABG as an alternative to redo coronary surgery (redo-OPCAB) [1, 6, 7]. However, most of these studies are based on small patient cohorts, and none of these studies has evaluated the impact of redo-OPCAB on long-term survival. In this study, we assess the safety and efficacy of redo-OPCAB versus redo-CABG using a combined end-point of serious postoperative complications as well as 1-, 5-, and 10-year survival."}

{"project":"2_test","denotations":[{"id":"28505298-24623172-28903782","span":{"begin":73,"end":74},"obj":"24623172"},{"id":"28505298-24623172-28903783","span":{"begin":171,"end":172},"obj":"24623172"},{"id":"28505298-16242445-28903784","span":{"begin":312,"end":313},"obj":"16242445"},{"id":"28505298-23321128-28903785","span":{"begin":315,"end":316},"obj":"23321128"},{"id":"28505298-16242445-28903786","span":{"begin":447,"end":448},"obj":"16242445"},{"id":"28505298-23321128-28903787","span":{"begin":450,"end":451},"obj":"23321128"},{"id":"28505298-26704310-28903788","span":{"begin":587,"end":588},"obj":"26704310"},{"id":"28505298-15245460-28903789","span":{"begin":732,"end":733},"obj":"15245460"},{"id":"28505298-24623172-28903790","span":{"begin":879,"end":880},"obj":"24623172"},{"id":"28505298-15245460-28903791","span":{"begin":882,"end":883},"obj":"15245460"},{"id":"28505298-18329464-28903792","span":{"begin":885,"end":886},"obj":"18329464"}],"text":"Redo cardiac surgery represents 5–8% of the current surgical practice [1–4]. In particular, reoperative coronary artery bypass grafting (redo-CABG) remains challenging [1–4] with prolonged operation time, bleeding, poor access to coronary targets and risk of coronary microembolization leading to complications [2, 3]. Redo-CABG has declined over the last decade to 2.5–4% of all coronary procedures, probably due to improved platelet inhibition [2, 3], use of more arterial conduits or to the use of percutaneous coronary intervention stenting to treat occluded grafts or new stenosis [5]. Poor risk profile in these patients may trigger complications associated with prolonged cardiopulmonary bypass and cardioplegic arrest time [6]. Studies from North America, Japan and India have highlighted the use of off-pump CABG as an alternative to redo coronary surgery (redo-OPCAB) [1, 6, 7]. However, most of these studies are based on small patient cohorts, and none of these studies has evaluated the impact of redo-OPCAB on long-term survival. In this study, we assess the safety and efficacy of redo-OPCAB versus redo-CABG using a combined end-point of serious postoperative complications as well as 1-, 5-, and 10-year survival."}

{"project":"MyTest","denotations":[{"id":"28505298-24623172-28903782","span":{"begin":73,"end":74},"obj":"24623172"},{"id":"28505298-24623172-28903783","span":{"begin":171,"end":172},"obj":"24623172"},{"id":"28505298-16242445-28903784","span":{"begin":312,"end":313},"obj":"16242445"},{"id":"28505298-23321128-28903785","span":{"begin":315,"end":316},"obj":"23321128"},{"id":"28505298-16242445-28903786","span":{"begin":447,"end":448},"obj":"16242445"},{"id":"28505298-23321128-28903787","span":{"begin":450,"end":451},"obj":"23321128"},{"id":"28505298-26704310-28903788","span":{"begin":587,"end":588},"obj":"26704310"},{"id":"28505298-15245460-28903789","span":{"begin":732,"end":733},"obj":"15245460"},{"id":"28505298-24623172-28903790","span":{"begin":879,"end":880},"obj":"24623172"},{"id":"28505298-15245460-28903791","span":{"begin":882,"end":883},"obj":"15245460"},{"id":"28505298-18329464-28903792","span":{"begin":885,"end":886},"obj":"18329464"}],"namespaces":[{"prefix":"_base","uri":"https://www.uniprot.org/uniprot/testbase"},{"prefix":"UniProtKB","uri":"https://www.uniprot.org/uniprot/"},{"prefix":"uniprot","uri":"https://www.uniprot.org/uniprotkb/"}],"text":"Redo cardiac surgery represents 5–8% of the current surgical practice [1–4]. In particular, reoperative coronary artery bypass grafting (redo-CABG) remains challenging [1–4] with prolonged operation time, bleeding, poor access to coronary targets and risk of coronary microembolization leading to complications [2, 3]. Redo-CABG has declined over the last decade to 2.5–4% of all coronary procedures, probably due to improved platelet inhibition [2, 3], use of more arterial conduits or to the use of percutaneous coronary intervention stenting to treat occluded grafts or new stenosis [5]. Poor risk profile in these patients may trigger complications associated with prolonged cardiopulmonary bypass and cardioplegic arrest time [6]. Studies from North America, Japan and India have highlighted the use of off-pump CABG as an alternative to redo coronary surgery (redo-OPCAB) [1, 6, 7]. However, most of these studies are based on small patient cohorts, and none of these studies has evaluated the impact of redo-OPCAB on long-term survival. In this study, we assess the safety and efficacy of redo-OPCAB versus redo-CABG using a combined end-point of serious postoperative complications as well as 1-, 5-, and 10-year survival."}